HUP0104909A2 - Elhízás kezelésére alkalmas 2-amino-4H-3,1-benzoxazin-4-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Elhízás kezelésére alkalmas 2-amino-4H-3,1-benzoxazin-4-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0104909A2 HUP0104909A2 HU0104909A HUP0104909A HUP0104909A2 HU P0104909 A2 HUP0104909 A2 HU P0104909A2 HU 0104909 A HU0104909 A HU 0104909A HU P0104909 A HUP0104909 A HU P0104909A HU P0104909 A2 HUP0104909 A2 HU P0104909A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- reduced
- obesity
- preparations
- formula
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 5
- 208000008589 Obesity Diseases 0.000 title abstract 3
- 235000020824 obesity Nutrition 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- MCDXWLAYOXBQBG-UHFFFAOYSA-N 2-amino-4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2CC(=O)N(N)OC2=C1 MCDXWLAYOXBQBG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000002148 esters Chemical group 0.000 abstract 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Chemical group 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
A jelen tal lm ny t rgy t képezik az új, (I) ltal nos képletűvegyületek, ezen vegyületek alkalmaz sa egy olyan enzim inhibi l s ra,amelynek jellemző hat smechanizmusa az észterfunkciók hidrolízise (invivo módon, mivel az enzim a természetben is előfordul), ezenvegyületek gyógyszerekben t"rténő alkalmaz sa, és kül"n"sen ezenvegyületek alkalmaz sa elhíz s, illetve elhíz ssal kapcsolatosrendellenességek megelőzésére és/vagy kezelésére. Szintén a tal lm nyt rgy t képezik elhíz s vagy elhíz ssal kapcsolatos rendellenességekmegelőzésére és/vagy kezelésére és nem gyógyszeres súlycs"kkenéselőmozdít s ra/segítésére szolg ló elj r sok, és a vegyületek alkalmazsa az előzőekben ismertetett indik ciók elleni gyógyszerkészítményekelő llít s n l. Az új vegyületekre vonatkozóan a tal lm ny t rgy t képezik az (I)ltal nos képletű elő llít s ra szolg ló elj r sok, az őket tartalmazókészítmények, illetve az ilyen készítmények elő llít s ra szolg lómódszerek. Az (I) ltal nos képletben A jelentése hattagú arom s vagyheteroarom s gyűrű, R1 jelentése egyenes vagy el gazó szénl ncúalkilcsoport (amely adott esetben egy vagy t"bb oxigénatommalmegszakított lehet), alkenil-, alkinil-, cikloalkil-, cikloalkenil-,aril-, aralkil-, reduk lt aralkil-, arilalkenil-, heteroaril-,heteroarilalkil-, heteroarilalkenil-, reduk lt aril-, reduk ltheteroaril-, vagy reduk lt heteroarilalkilcsoport, vagy ezen csoportokhelyettesített sz rmazékai, R2 jelentése hidrogénatom vagy b rmely, azR1 szubsztituens jelentésénél megadott csoport. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9900416.0A GB9900416D0 (en) | 1999-01-08 | 1999-01-08 | Inhibitors |
PCT/GB2000/000031 WO2000040569A1 (en) | 1999-01-08 | 2000-01-06 | 2-amino-benzoxazinone derivatives for the treatment of obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0104909A2 true HUP0104909A2 (hu) | 2002-04-29 |
HUP0104909A3 HUP0104909A3 (en) | 2004-11-29 |
Family
ID=10845777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104909A HUP0104909A3 (en) | 1999-01-08 | 2000-01-06 | 2-amino-benzoxazinone derivatives for the treatment of obesity, process for their preparation and medicaments containing them |
Country Status (22)
Country | Link |
---|---|
US (2) | US6656934B2 (hu) |
EP (1) | EP1144395B1 (hu) |
JP (1) | JP2002534419A (hu) |
KR (1) | KR100615914B1 (hu) |
CN (1) | CN100480245C (hu) |
AR (1) | AR022203A1 (hu) |
AT (1) | ATE293610T1 (hu) |
AU (1) | AU770342B2 (hu) |
CA (1) | CA2359987C (hu) |
DE (1) | DE60019556T2 (hu) |
DK (1) | DK1144395T3 (hu) |
ES (1) | ES2240051T3 (hu) |
GB (1) | GB9900416D0 (hu) |
HK (1) | HK1047284A1 (hu) |
HU (1) | HUP0104909A3 (hu) |
MY (1) | MY129247A (hu) |
NO (1) | NO321058B1 (hu) |
NZ (1) | NZ512739A (hu) |
PL (1) | PL350412A1 (hu) |
PT (1) | PT1144395E (hu) |
RU (1) | RU2244711C2 (hu) |
WO (1) | WO2000040569A1 (hu) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9900416D0 (en) * | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
CA2286451A1 (en) | 1999-10-14 | 2001-04-14 | Grant A. Mitchell | Hormone-sensitive lipase mediated male infertility |
GB0001572D0 (en) | 2000-01-24 | 2000-03-15 | Alizyme Therapeutics Ltd | Inhibitors |
SI1296656T1 (sl) | 2000-06-27 | 2006-12-31 | Hoffmann La Roche | Postopek priprave sestavka |
SI1307264T1 (en) | 2000-07-28 | 2005-02-28 | F. Hoffmann-La Roche Ag | New pharmaceutical composition |
KR100556324B1 (ko) | 2000-07-28 | 2006-03-03 | 에프. 호프만-라 로슈 아게 | 리파제 억제제 및 담즙산 격리제를 포함하는 약학 조성물 |
US6730319B2 (en) | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
US20030027786A1 (en) | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
DE10135027A1 (de) * | 2001-07-18 | 2003-02-06 | Solvay Pharm Gmbh | Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen |
EP1578987A2 (en) | 2001-08-03 | 2005-09-28 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
US6943001B2 (en) | 2001-08-03 | 2005-09-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
MXPA04001328A (es) | 2001-08-22 | 2004-05-05 | Aventis Pharma Gmbh | Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso. |
MXPA04001922A (es) * | 2001-08-30 | 2005-03-07 | Alizyme Therapeutics Ltd | Tieno-(1,3)-oxazin-4-onas con actividad inhibidora de lipasa. |
MXPA04001850A (es) | 2001-08-31 | 2004-06-15 | Aventis Pharma Gmbh | Derivados de diarilcicloalquilo, procedimientos para su preparacion y su utilizacion como agentes activadores de ppar. |
US6884812B2 (en) | 2001-08-31 | 2005-04-26 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals |
US7399777B2 (en) | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
EA009368B1 (ru) | 2001-12-20 | 2007-12-28 | Оси Фармасьютикалз, Инк. | Соединения-ингибиторы липазы поджелудочной железы, их синтез и применение |
US7078404B2 (en) | 2002-04-11 | 2006-07-18 | Sanofi-Aventis Deutschland Gmbh | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use |
US7223796B2 (en) | 2002-04-11 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use |
US7049341B2 (en) | 2002-06-07 | 2006-05-23 | Aventis Pharma Deutschland Gmbh | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use |
US7262220B2 (en) | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
BR0312697A (pt) | 2002-07-12 | 2005-04-26 | Aventis Pharma Gmbh | Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento |
US20040157922A1 (en) | 2002-10-04 | 2004-08-12 | Aventis Pharma Deutschland Gmbh | Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments |
US7208504B2 (en) | 2002-10-12 | 2007-04-24 | Sanofi-Aventis Deutschland Gmbh | Bicyclic inhibitors of hormone sensitive lipase |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
US8372430B2 (en) | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
US20040242583A1 (en) | 2003-01-20 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use |
US7179941B2 (en) | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7196114B2 (en) | 2003-02-17 | 2007-03-27 | Sanofi-Aventis Deutschland Gmbh | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use |
DE10308351A1 (de) | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10308352A1 (de) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
WO2004110338A2 (en) * | 2003-06-12 | 2004-12-23 | Biomas Ltd. | Methods of treating obesity and related disorders using tellurium and selenium compounds |
US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (de) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
US7241787B2 (en) | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
US7402674B2 (en) | 2004-01-31 | 2008-07-22 | Sanofi-Aventis Deutschland Gmbh, | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
US7498341B2 (en) | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
EP1586573B1 (en) | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
MX2007004889A (es) | 2004-10-25 | 2007-09-11 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados. |
DE102004059470A1 (de) * | 2004-12-10 | 2006-06-14 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von Carbaminsäureester-Derivaten |
US20090082435A1 (en) * | 2005-04-28 | 2009-03-26 | The Regents Of The University Of California | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders |
DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
US7737146B2 (en) | 2005-10-25 | 2010-06-15 | Council Of Scientific And Industrial Research | Compound, useful for pancreatic lipase inhibition and the process for isolation thereof |
ES2427247T3 (es) | 2006-03-13 | 2013-10-30 | Kyorin Pharmaceutical Co., Ltd. | Aminoquinolonas como inhibidores de GSK-3 |
DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
MX2009002282A (es) | 2006-09-07 | 2009-03-20 | Nycomed Gmbh | Tratamiento de combinacion para diabetes mellitius. |
DE102007002260A1 (de) | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms |
DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
CA2963857A1 (en) | 2007-06-04 | 2008-12-11 | Ben-Gurion University Of The Negev Research And Development Authority | Tri-aryl compounds and compositions comprising the same |
ES2371800T3 (es) | 2007-09-11 | 2012-01-10 | Kyorin Pharmaceutical Co.,Ltd. | Cianoaminoquinolonas como inhibidores de gsk-3. |
BRPI0816814B1 (pt) | 2007-09-12 | 2021-08-31 | Kyorin Pharmaceutical Co. Ltd | Composto, composição farmacêutica e uso de um composto |
DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
JP2010254623A (ja) * | 2009-04-24 | 2010-11-11 | Takeda Chem Ind Ltd | ベンゾオキサジノン化合物の結晶 |
CA2771278A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2482823A2 (en) | 2009-10-02 | 2012-08-08 | Sanofi | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
EA024059B1 (ru) * | 2011-01-13 | 2016-08-31 | Новартис Аг | Гетероциклические производные и их применение в лечении неврологических расстройств |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP6657101B2 (ja) | 2013-11-05 | 2020-03-04 | ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ | 糖尿病及びそれから生じる疾患合併症の治療のための化合物 |
CN104374836A (zh) * | 2014-09-19 | 2015-02-25 | 安徽安科生物工程(集团)股份有限公司 | 西替利司他及有关杂质的hplc测定方法 |
CN105622539B (zh) * | 2016-03-11 | 2016-11-23 | 中山万汉医药科技有限公司 | 一种西替利司他的制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3450700A (en) * | 1966-12-20 | 1969-06-17 | Upjohn Co | 2-tertiary amino-4h-3,1-benzoxazin-4-ones |
DE2315303A1 (de) * | 1973-03-27 | 1974-10-17 | Bayer Ag | Verfahren zur herstellung von n-substituierten 2-amino-3,1-benzoxazin-4-onen |
US4657893A (en) * | 1984-05-09 | 1987-04-14 | Syntex (U.S.A.) Inc. | 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors |
NZ210669A (en) * | 1983-12-27 | 1988-05-30 | Syntex Inc | Benzoxazin-4-one derivatives and pharmaceutical compositions |
US4745116A (en) | 1985-06-25 | 1988-05-17 | Syntex (U.S.A.) Inc. | 2-oxy-4H-3,1-benzoxazin-4-ones and related compounds and pharmaceutical use |
US4665070A (en) | 1985-06-25 | 1987-05-12 | Syntex (U.S.A.) Inc. | 2-oxy-4H-3,1-benzoxazin-4-ones and pharmaceutical use |
US5652237A (en) * | 1994-09-09 | 1997-07-29 | Warner-Lambert Company | 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes |
US5985872A (en) * | 1995-05-24 | 1999-11-16 | G.D. Searle & Co. | 2-amino-benzoxazinones for the treatment of viral infections |
US5776756A (en) * | 1995-08-31 | 1998-07-07 | Toyo Hakko Co., Ltd. | Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity |
GB9900416D0 (en) * | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
-
1999
- 1999-01-08 GB GBGB9900416.0A patent/GB9900416D0/en not_active Ceased
-
2000
- 2000-01-05 AR ARP000100028A patent/AR022203A1/es active IP Right Grant
- 2000-01-06 PL PL00350412A patent/PL350412A1/xx not_active Application Discontinuation
- 2000-01-06 AU AU18845/00A patent/AU770342B2/en not_active Ceased
- 2000-01-06 CA CA002359987A patent/CA2359987C/en not_active Expired - Fee Related
- 2000-01-06 CN CNB008036217A patent/CN100480245C/zh not_active Expired - Fee Related
- 2000-01-06 WO PCT/GB2000/000031 patent/WO2000040569A1/en active Search and Examination
- 2000-01-06 DE DE60019556T patent/DE60019556T2/de not_active Expired - Lifetime
- 2000-01-06 DK DK00900081T patent/DK1144395T3/da active
- 2000-01-06 AT AT00900081T patent/ATE293610T1/de not_active IP Right Cessation
- 2000-01-06 NZ NZ512739A patent/NZ512739A/en not_active IP Right Cessation
- 2000-01-06 ES ES00900081T patent/ES2240051T3/es not_active Expired - Lifetime
- 2000-01-06 MY MYPI20000045A patent/MY129247A/en unknown
- 2000-01-06 KR KR1020017008596A patent/KR100615914B1/ko not_active IP Right Cessation
- 2000-01-06 PT PT00900081T patent/PT1144395E/pt unknown
- 2000-01-06 EP EP00900081A patent/EP1144395B1/en not_active Expired - Lifetime
- 2000-01-06 HU HU0104909A patent/HUP0104909A3/hu unknown
- 2000-01-06 RU RU2001121983/04A patent/RU2244711C2/ru not_active IP Right Cessation
- 2000-01-06 JP JP2000592277A patent/JP2002534419A/ja not_active Withdrawn
-
2001
- 2001-07-06 US US09/901,868 patent/US6656934B2/en not_active Expired - Fee Related
- 2001-07-06 NO NO20013380A patent/NO321058B1/no not_active IP Right Cessation
-
2002
- 2002-11-27 US US10/306,375 patent/US7776853B2/en not_active Expired - Fee Related
- 2002-12-12 HK HK02109007.0A patent/HK1047284A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104909A2 (hu) | Elhízás kezelésére alkalmas 2-amino-4H-3,1-benzoxazin-4-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0401537A2 (hu) | Tiohidantoin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására | |
HUP0104495A2 (hu) | N-szubsztituált 2-ciano-pirrolidinek és ezeket tartalmazó gyógyászati készítmények | |
HUP0203190A2 (hu) | Glükopiranoziloxi-pirazol-származékok, az ezeket tartalmazó gyógyászati készítmények, valamint az ezek előállításához használható köztitermékek | |
HUP0002960A2 (hu) | Aril-oxi-szulfonil-amino-hidroxámsav-származékok | |
HUP0102556A2 (hu) | Benzolszulfonamidszármazékok és felhasználásuk gyógyszerkészítményként és eljárás a vegyületek előállítására | |
HUP9701690A2 (hu) | Gombaellenes hatású tetrahidrofuránszármazékok és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0402503A2 (hu) | Pirrolidinonszármazékok és a vegyületeket tartalmazó gyógyászati készítmények | |
MY102866A (en) | Amide derivatives. | |
HUP0104579A2 (hu) | GLP-1 analógok, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása | |
HUP0102470A2 (hu) | Retinoidrokon receptorok funkcióját szabályozó 1,3-azol-származékok és alkalmazásuk | |
HUP0104578A2 (hu) | Nem szteroid gyulladásgátló szerek, valamint ezek hatóanyagait képező vegyületek | |
HUP0102022A2 (hu) | Gamma-amino-vajsavat vagy származékait tartalmazó stabilizált gyógyszerkészítmények és az előállításukra szolgáló eljárás | |
FI960722A0 (fi) | Verisuonia supistavia substituoituja aryylioksialkyylidiamiineja | |
DE69401584T2 (de) | Beta,beta-dimethyl-4-piperidinethanamin-derivate als inhibitoren der cholesterin-biosynthese | |
HUP9700005A2 (hu) | 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények | |
HUP0100558A2 (hu) | S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben | |
HUP9701588A2 (hu) | Új flavonszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0100184A2 (hu) | Szubsztituált 2-(benzil-amino)-2-fenil-acetamid-vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
CA2461963A1 (en) | Cyclic amine compounds | |
HUP0301030A2 (hu) | Kardiális aritmiák kezelésére alkalmazható új aza-biciklooktán-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP9900621A2 (hu) | 3,4-Diszubsztituált fenil-etanol-amino-tetralin-karboxamid-származékok, előállításuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0203884A2 (hu) | Kristályos oximinoalkánsav-származékok és cukorbaj elleni alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
MD1687F2 (en) | Arylthiocompounds, pharmaceutical composition, methods of bacterial and viral infections treatment | |
HUP0204217A2 (en) | Novel a-500359 derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: NORGINE B.V., NL Free format text: FORMER OWNER(S): ALIZYME THERAPEUTICS LTD., GB |
|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |